Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Q-Med AB    0GUA   SE0000426462

News SummaryMost relevantAll newsSector newsTweets 

Q-MED AB : Annual Report 2009 Q-Med AB (publ)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/08/2010 | 03:00pm CEST

Q-Med's Annual Report can be downloaded from the company's website at
www.q-med.com as from today.

The Annual Report will be sent to Q-Med shareholders who have actively requested
this and to other stakeholders during the week commencing April 12.

Queries should be addressed to:

Karin Falck, PR & Corporate Communications
Tel: +46 70 974 9015

Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta(TM) for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q?Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: [email protected]
. Web: www.q-med.com .


Press Release (PDF): http://hugin.info/130306/R/1401490/356509.pdf

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on Q-MED AB
2010 Q-MED AB : Panel Meeting Solesta(TM) December 2, 2010
2010 Q-MED AB : New CEO and new Chairman of the Board at Q-Med AB
2010 Q-MED AB : Interim report January-June 2010
2010 Q-MED AB : invites to Q2 conference call
2010 Q-MED AB : Annual General Meeting of Q-Med AB (publ)
2010 Q-MED AB : Maria Carell new CEO for Q-Med AB
2010 Q-MED AB : Interim report January-March 2010
2010 Q-MED AB : invites to Q1 conference call
2010 Q-MED AB : and Oceana Therapeutics achieve key milestone with the submission of ..
2010 Q-MED AB : Annual Report 2009 Q-Med AB (publ)
More news
Sector news : Specialty & Advanced Pharmaceuticals
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
More sector news : Specialty & Advanced Pharmaceuticals
Income Statement Evolution
More Financials
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE16.16%115 610
MERCK KGAA12.10%16 065
KYOWA HAKKO KIRIN CO L..29.91%10 787
More Results